PLX vs SRPT

For growth investors, Sarepta Therapeutics, Inc.

(SRPT) is the stronger pick with 15. 6% revenue growth year-over-year, versus -1. 2% for Protalix BioTherapeutics, Inc. (PLX). Analysts rate Protalix BioTherapeutics, Inc. (PLX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Protalix BioTherapeutics, Inc.

(PLX) delivered a total return of -34. 9%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: SRPT returned +18. 0% versus PLX's -75. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protalix BioTherapeutics, Inc.

(PLX) is the lower-risk stock at 1. 38β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 47% more volatile than PLX relative to the S&P 500. On balance sheet safety, Protalix BioTherapeutics, Inc. (PLX) carries a lower debt/equity ratio of 17% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sarepta Therapeutics, Inc.

(SRPT) is pulling ahead at 15. 6% versus -1. 2% for Protalix BioTherapeutics, Inc. (PLX). On earnings-per-share growth, the picture is similar: Protalix BioTherapeutics, Inc. grew EPS -329. 8% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Protalix BioTherapeutics, Inc.

(PLX) is the more profitable company, earning -12. 5% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps -12. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PLX leads at -10. 4% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 6. 9x forward P/E versus 9. 2x for Protalix BioTherapeutics, Inc. — 2. 3x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protalix BioTherapeutics, Inc.

(PLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PLX: -75. 5%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLX is a small-cap quality compounder stock; SRPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.